FY2020 Financial Results Presentation

from the beginning

FY2020 Financial Results Presentation

Forward-Looking Statements

1. FY2020 Financial Results

Overview of FY2020 Results

Revenue

Operating Profit

Special Items

Profit Attributable to Owners of the Company

Revenue: Major Business Units (incl. Forex Impact)

Revenue: Major Products in Japan

2. FY2021 Forecast

FY2021 Forecast

3. Business Update

ENHERTU

ENHERTU: Initiatives to Maximize Value

ENHERTU: Revenue

Initiatives for Business Growth in Each Region

Initiatives for Business Growth in Each Region

EDOXABAN

LIXIANA: Growth in Japan

EDOXABAN: Growth in Each Country

Streamlining Assets

Cash Generation by Streamlining Assets

Shareholder Returns

Shareholder Returns

4. R&D Update

Major progress in FY2020

3ADCs: Major Progress of Enhertu in FY2020

3ADCs: Major Progress of Enhertu in FY2020

3ADCs: Major Progress of Dato-DXd in FY2020

3ADCs: Major Progress of HER3-DXd in FY2020

3ADCs: Major presentations at conferences in FY2020

ASCO 2021 Advance of the Year

Enhertu received the Japanese Prime Minister's Award

Alpha: Major Progress in FY2020

ASCO 2021

Planned Presentation at ASCO 2021(6/4 to 6/8, Virtual Meeting)

ASCO 2021: IR Conference Call

News Flow

News Flow

5. Update of Actions against COVID-19

Update of Actions against COVID-19

6. Appendix

Major R&D Milestones in FY2021 (3ADCs)

Major R&D Milestones in FY2021 (Alpha)

Major R&D Pipeline: 3ADCs

Major R&D Pipeline: Alpha

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8

• Q&A 9

• Q&A 10

• Q&A 11